In this respect, two recent publications using the same cohort showed that patients treated with SGLT-2i have lower levels of IL-6 [19, 20], with a mechanism of action network model identifying IL-6 as a SGLT-2i-sensitive, central hub in the development and progression of diabetic nephropathy [19]. Here, IL6 is linked to diabetic kidney disease.